Methylprednisolone hemisuccinate
Phase 3Small molecule
Methylprednisolone hemisuccinate is one of 6 small molecule programs targeting ISS. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in ISS
#DrugCompanyPhaseTrials
1Ginaton
PPeking University People's Hospital
Phase 3
Myrbetriq
AstellasPhase 1
Methylprednisolone hemisuccinate
BBBB-Therapeutics B.V.
Phase 3
Acellular Adipose Tissue (AAT)
JJohns Hopkins University
Phase 2
Reboxetine
UUniversity of Zurich
Preclinical
Psilocybine
UUniversity of Zurich
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis1 trial
ISS1 trial
The Effect of PAP on ISSHL Comorbided With OSA
Recruiting·—·Phase 4·NCT04192656·102 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBBB-Therapeutics B.V.